Quetiapine fumarate augmentation for patients with a primary anxiety disorder or a mood disorder: a

Efficacy of quetiapine in treatment of anxiety disorders

  1. aemetha
    Study Author(s):
    Yi-Chih Chen, Chih-Ken Chen, and Liang-Jen Wang
    Journal Name:
    BMC Psyciatry
    Publication Date:
    2012
    Abstract
    Background: Comorbid anxiety symptoms,in patients with a primary anxiety disorder or a mood disorder, leads to
    poor patient outcomes and burdens the healthcare system. This pilot study evaluated the feasibility of
    extended-release quetiapine fumarate (quetiapine XR) for the treatment of patients with either a primary anxiety
    disorder or a mood disorder with comorbid anxiety symptoms compared to a placebo, as an adjunct to
    antidepressant therapy.
    Methods: Thirty-nine patients with a diagnosis of a primary anxiety disorder or a mood disorder with comorbid
    anxiety symptoms were enrolled in this study. Patients with a stable dose of antidepressant therapy were
    randomized according to a 2:1 probability of receiving either quetiapine XR or a placebo adjunctive treatment for
    8 weeks. The efficacy was assessed by the Hamilton Anxiety Rating Scale (HAM-A) and the Clinical Global
    Impression of severity (CGI-S) score at baseline, week 1, 4, and 8.
    Results: A total of 35 patients were included in this intention-to treat (ITT) population for the efficacy analysis
    (quetiapine XR: 22 patients; placebo: 13 patients). At week 4, statistically significant differences were observed on
    both the HAM-A score (p = 0.003) and the CGI-S score (p = 0.025), favouring the quetiapine XR (−13.00 ± 4.14)
    compared to placebo (−6.63 ± 5.42). However, no statistically significant difference was observed between the two
    groups with regard to changes from the baseline to week 8 on the HAM-A score (p = 0.332) or the CGI-S score
    (p = 0.833).
    Conclusions: Augmentation of antidepressant treatment with quetiapine XR did not result in clinical improvement
    according to the outcome measure of anxiety using the HAM-A and CGI-S scores at week 8, among the patients
    with either a primary anxiety disorder or a mood disorder with comorbid anxiety symptoms. However, treatment
    with quetiapine XR as an adjunct to antidepressant therapy appeared to provide a short-term benefit at 4 weeks.
    Further study is needed with a larger sample size, randomized controlled design and control of the
    dosage prescribed.